24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine

• Status: Completed
• Trial end date: 2004-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if twice-daily Lispro low mixture (75/25) will result in lower post prandial blood glucose readings versus once-daily glargine plus oral diabetic medications.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Hypoglycemic Agents; Insulin Glargine; Insulin Lispro

Criteria

Inclusion Criteria:

• Have type 2 diabetes

• Have inadequate overall glycemic control (hemoglobin A1c greater than or equal to 7.0% and less than or equal to 12.0%) at or within 4 weeks prior to Visit 1

• Have used:

• single or multiple OAMs for at least 3 months immediately prior to entering the study, including metformin, sulfonylurea, meglitinides (repaglinide, nateglinide), or alpha glucosidase inhibitors (acarbose, miglitol); or

• insulin (once or twice daily) for at least 3 months immediately prior to entering the study; or

• a combination of the above.

• Are greater than or equal to 21 and less than 80 years of age

• As determined by the investigator, are capable and willing to:

• comply with their prescribed diet and medication regimen,

• perform self blood glucose monitoring,

• use the patient diary as required for this protocol,

• participate in two 24 hour inpatient assessments

Exclusion Criteria:

• Have used a thiazolidinedione (pioglitazone or rosiglitazone) during the 3 months prior to entry into the study

• Are currently treated with a meglitinide without sulfonylurea

• Have a known allergy or intolerance to insulin lispro mix 75/25, insulin glargine, or metformin

• Have plasma creatinine greater than or equal to 1.5 mg/dL (for males) or greater than or equal to 1.4 mg/dL (for females) for patients who will be treated with metformin or; greater than 2 mg/dL for patients treated with other OAMs, as determined by a local laboratory

• Have received chronic (lasting longer than 2 weeks), systemic glucocorticoid therapy (excluding topical and inhaled preparations) within 4 weeks immediately prior to Visit 1